U.S. Food and Drug Administration Product Analyst Salaries in Crestview, FL
The average U.S. Food and Drug Administration Product Analyst in Crestview, FL earns an estimated $136,235 annually, which includes an estimated base salary of $116,810 with a $19,425 bonus. U.S. Food and Drug Administration's Product Analyst compensation is $21,241 more than the US average for a Product Analyst. Product Analyst salaries at U.S. Food and Drug Administration in Crestview, FL can range from $50,000 - $505,555.
In Crestview, FL, The Product Department at U.S. Food and Drug Administration earns $2,217 more on average than the Legal Department.
Last updated 3 years ago.
- $116,810
- avg. base
- $19,425
- avg. bonus
Product Analyst Salaries at U.S. Food and Drug Administration
In Crestview, FL, Product Analysts earn $3,247 more than Product Managers, and $34,301 less than Senior Product Managers.
Compensation at U.S. Food and Drug Administration by Department
In Crestview, FL, The Product Department averages $2,217 more than the Legal Department, and $44,670 less than the Enterprise Risk Department
Product Analyst Compensation by Gender (All Companies)
The average female Product Analyst at companies similar size to U.S. Food and Drug Administration reported making $131,454, while the average male Product Analyst at similar sized companies reported making $138,128.
Product Analyst Compensation by Ethnicity (All Companies)
The average Asian or Pacific Islander Product Analyst at companies similar size to U.S. Food and Drug Administration reported making $141,695, while the average African American/Black Product Analyst at similar sized companies reported making $108,963.
How Product Analysts at U.S. Food and Drug Administration Rate Their Compensation
The majority of Product Analysts at U.S. Food and Drug Administration believe they're compensated fairly. 100% of Product Analysts at U.S. Food and Drug Administration say they receive annual bonuses, and the vast majority (71%) are satisfied with their benefits. See more compensation ratings at U.S. Food and Drug Administration
